Novo Nordisk is among the best in the pharmaceutical industry with a score of 81 in the 2015 Dow Jones Sustainability World Index.
Submitted by Novo Nordisk
Novo Nordisk stays in top of the pharmaceutical sector on the 2015 Dow Jones Sustainability World Index with a score of 81 out of a possible 100. The company’s overall score falls 3 points from 2014 and is 7 points behind Roche, the 2015 industry leader.
The 2015 ranking marks the 16th straight year Novo Nordisk has been included in the Dow Jones Sustainability Index.
“Novo Nordisk has a long-term commitment to improve care for the millions of people living with diabetes,” says Charlotte Ersbøll, corporate vice president, Corporate Stakeholder Engagement at Novo Nordisk. “We are pleased to have improved in several of our focus areas and to be recognised for the efforts the organisation has put behind Novo Nordisk’s sustainable approach. As part of our commitment to manage our business with financial, social and environmental responsibility, we will be analysing the results to better understand where and how improvements can be made.”
Compared to 2014, Novo Nordisk’s score dropped 1 point in the economic dimension, 10 points in the environmental dimension and 3 points in the social dimension.
Advancements and setbacks
Among the 24 categories evaluating Novo Nordisk’s sustainability performance, the company is leading the industry in two: Innovation Management (score of 85) and Corporate Citizenship and Philanthropy (score of 100).
Top five advancements in score include:
Product Quality and Recall management went up 18% to 67 (from 57 in 2014)
Supply Chain Management went up 15% to 93 (from 81 in 2014)
Occupational Health and Safety went up 14% to 73 (from 64 in 2014)
Strategy to Improve Access to Drugs or Products went up 13% to 90 (from 80 in 2014)
Environmental Reporting went up 11% to 90 (from 81 in 2014)
Top five setbacks in score include:
Operational Eco-Efficiency went down 53% to 30 (from 64 in 2014)
Bioethics went down 29% to 71 (from 100 in 2014)
Health Outcome Contribution went down 25% to 70 (from 93 in 2014)
Risk & Crisis Management went down 19% to 79 (from 97 in 2014)
Customer Relationship Management went down 11% to 75 (from 84 in 2014)
Scoring for the Dow Jones Sustainability Index is based on companies’ self-reported data which is used to assess performance in 24 categories divided into economic, environmental and social dimensions.
About the Dow Jones Sustainability Index
The Dow Jones Sustainability Index is investor-led and serves as benchmarks for investors who integrate sustainability considerations into their portfolios and look for best-in-class performance. The Dow Jones Sustainability Index track the world’s leading companies in terms of their social, environmental and economic performance.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
More from Novo Nordisk